Thrombopoietin receptor agonists and thrombotic risk in immune thrombocytopenia
Revista Hemostasia y Trombosis · 30.10.2026 · 2 (3)
DOI: 10.24875/rht.m24000009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Hemostasia y Trombosis, online erschienen am 30.10.2026. Verfasst von Carmen Albo-López und 4 weiteren Autor:innen.
Abstract (Originalsprache)
The thrombopoietin receptor agonists are undoubtedly the first choice as a second-line treatment in primary immune thrombocytopenia, due to their effectiveness and good safety profile.Although debatable, some authors consider them inappropriate as a therapeutic option in patients at high thrombotic risk, perhaps overlooking the thrombogenic nature of the disease, which may restrict their use and limit therapeutic benefit in some patients.We reviewed the literature and explored thrombotic risk not only associated with thrombopoietin receptor agonists, but also with other therapeutic options and the disease itself.
Zitieren
APA
Albo-López, C., Rodríguez-López, M., López-Ansoar, M. E., Domínguez-Muñiz, Ó., & Iglesias-Varela, R. (2026). Thrombopoietin receptor agonists and thrombotic risk in immune thrombocytopenia. Revista Hemostasia y Trombosis, 2(3). https://doi.org/10.24875/rht.m24000009
Vancouver
Albo-López C, Rodríguez-López M, López-Ansoar ME, Domínguez-Muñiz Ó, Iglesias-Varela R. Thrombopoietin receptor agonists and thrombotic risk in immune thrombocytopenia. Revista Hemostasia y Trombosis. 2026;2(3). doi:10.24875/rht.m24000009
BibTeX
@article{AlboLpez2026,
author = {Albo-López, Carmen and Rodríguez-López, Manuel and López-Ansoar, María E. and Domínguez-Muñiz, Óscar and Iglesias-Varela, Raquel},
title = {Thrombopoietin receptor agonists and thrombotic risk in immune thrombocytopenia},
journal = {Revista Hemostasia y Trombosis},
year = {2026},
volume = {2},
number = {3},
doi = {10.24875/rht.m24000009}
}
EUVIMED